IGFBP2 Plays an Essential Role in Cognitive Development during Early Life. by Khan, Shumsuzzaman et al.
UC San Diego
UC San Diego Previously Published Works
Title
IGFBP2 Plays an Essential Role in Cognitive Development during Early Life.
Permalink
https://escholarship.org/uc/item/3pj8t9cb
Journal
Advanced science (Weinheim, Baden-Wurttemberg, Germany), 6(23)
ISSN
2198-3844
Authors
Khan, Shumsuzzaman
Lu, Xinjiang
Huang, Qingyao
et al.
Publication Date
2019-12-01
DOI
10.1002/advs.201901152
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1901152 (1 of 14) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedscience.com
Full PaPer
IGFBP2 Plays an Essential Role in Cognitive Development 
during Early Life
Shumsuzzaman Khan, Xinjiang Lu, Qingyao Huang, Jiawei Tang, Jian Weng, Zhi Yang, 
Minchao Lv, Xiaokang Xu, Fangyuan Xia, Mengchen Zhang, Yi Li, Shuangshuang Liu, 
Gareth Leng, Nicholas Spitzer, Jizeng Du, and Xuequn Chen*
S. Khan,[+] X. Lu, Q. Huang, J. Tang, J. Weng, Z. Yang, M. Lv, X. Xu, F. Xia, 
M. Zhang, Y. Li, S. Liu, Prof. J. Du, Prof. X. Chen
Institute of Neuroscience
Department of Neurobiology, and Department of Neurology  
of Second Affiliated Hospital
NHC and CAMS Key Laboratory of Medical Neurobiology
Key Laboratory of Medical Neurobiology of Zhejiang Province
Zhejiang University School of Medicine
Hangzhou 310058, China
E-mail: chewyg@zju.edu.cn
Prof. G. Leng
Experimental Physiology
University of Edinburgh
Edinburgh EH8 9XD, UK
Prof. N. Spitzer
University of California, San Diego
La Jolla, CA 92093-0357, USA
The ORCID identification number(s) for the author(s) of this article 
can be found under https://doi.org/10.1002/advs.201901152.
DOI: 10.1002/advs.201901152
1. Introduction
Understanding the mechanisms of 
early cognitive development has great 
importance as it could help to improve 
cognitive therapy.[1–3] The IGF family 
includes neurotrophic factors and medi-
ates learning and memory.[1–3] Sensory 
experience regulates cortical inhibition 
by IGF1[3] and IGF1 restores synaptic 
deficits.[4] IGF-1 receptors regulate trans-
mission via mitochondrial mediation in 
the hippocampus.[5] IGF-1 also restores 
corticospinal axon-dependent functions 
in adult mice and is a growth facili-
tator required for axon regeneration in 
adult mice and rats with spinal cord 
injury.[6,7] IGF-II enhances memory and 
prevents forgetting via IGF-II receptors.[1]
The expression of insulin-like growth 
factor binding protein-2 (IGFBP2) 
in the hippocampus increases during postnatal develop-
ment and is associated with learning and memory, but 
how it affects cognitive enhancement is unknown. IGFBP2 
is one of six members of the superfamily of IGF-binding 
proteins, most of which are synthesized in the liver and 
released into the circulation to regulate the bioavailability 
of IGFs I and II and their tissue distribution.[2,8] IGFBP2 
is present in the central nervous system from the embryo 
and neonate to adulthood and is highly expressed in the 
developing brain, secreted by both primary astrocytes and 
fetal neurons. IGFBP2 expression is correlated with brain 
development, astrocyte proliferation, and neurite out-
growth. Its expression is coordinated with that of IGF1 in 
the cerebellum and in developing sensory networks, but 
not in the hippocampus,[2,9] suggesting that it may have a 
hippocampus-specific function.
Here we investigate whether IGFBP2 is essential for cogni-
tive development and how it affects information processing in 
the hippocampus. Using transgenic mice deficient in IGFBP2 
(igfbp2−/−) we show that IGFBP2 is necessary for spine growth 
and neuronal proliferation in postnatal mice, and that it acts as 
a neuromodulator and coordinator of Hebbian and homeostatic 
plasticity in a cell-type specific manner. Through these actions 
it integrates metaplastic signals to facilitate long-term potentia-
tion (LTP) and spatial learning and memory.
Identifying the mechanisms underlying cognitive development in early 
life is a critical objective. The expression of insulin-like growth factor 
binding protein 2 (IGFBP2) in the hippocampus increases during neonatal 
development and is associated with learning and memory, but a causal 
connection has not been established. Here, it is reported that neurons and 
astrocytes expressing IGFBP2 are distributed throughout the hippocampus. 
IGFBP2 enhances excitatory inputs onto CA1 pyramidal neurons, facilitating 
intrinsic excitability and spike transmission, and regulates plasticity at 
excitatory synapses in a cell-type specific manner. It facilitates long-term 
potentiation (LTP) by enhancing N-methyl-d-aspartate (NMDA) receptor-
dependent excitatory postsynaptic current (EPSC), and enhances neurite 
proliferation and elongation. Knockout of igfbp2 reduces the numbers of 
pyramidal cells and interneurons, impairs LTP and cognitive performance, 
and reduces tonic excitation of pyramidal neurons that are all rescued 
by IGFBP2. The results provide insight into the requirement for IGFBP2 
in cognition in early life.
© 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. 
KGaA, Weinheim. This is an open access article under the terms of the 
Creative Commons Attribution License, which permits use, distribution 
and reproduction in any medium, provided the original work is properly 
cited.
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2. Results
2.1. IGFBP2 Is Required for Normal Hippocampal Development
IGFBP2-immunopositive neurons were distributed throughout 
the hippocampus (CA1, CA3, and DG) and in cortical layers 
1 and 2/3 in wild-type igfbp2+/+ mice at postnatal days 15, 45, 
and 60 (p15, p45, and p60) (Figure 1A–D and Figure S1A, 
Supporting Information). In the hippocampus, IGFBP2 was 
expressed in pyramidal neurons (Figure 1A,B) and in GABAe-
rgic interneurons (Figure 1C), while IGFBP2-positive astrocytes 
were found in the molecular layer (Figure 1D). IGFBP2 was 
expressed in GABAergic interneurons in CA1, while in the DG 
there were GABAergic interneurons (glutamic acid decarboxy-
lase (GAD)-positive cells) without IGFBP2 immunostaining 
in igfbp2+/+ mice (Figure 1C). At p180, IGFBP2 neurons were 
fewer in number and restricted to CA3, while, as expected, 
igfbp2−/− p45 mice failed to show IGFBP2-immunoreactivity 
(Figure 1E).
There was no marked difference in the size and shape of the 
brain and hippocampus between wild-type and igfbp2−/− mice 
(Figure 1F–H), but igfbp2−/− mice had fewer cells and a lower 
optical density in the stratum pyramidale (SP) of the CA1 
region than wild-type mice (Figure 1G–J and Figure S1A–E, 
Supporting Information), and markedly fewer interneurons 
throughout the hippocampus (CA1, CA3, and the DG) and 
cortex (layers 1 and 2/3) (Figure S1C,D, Supporting Infor-
mation). There was also lower expression of transcripts of 
the N-methyl-d-aspartate receptor (NMDAR) subunit NR2B 
and spine-associated-Rap-specific GTPase-activating pro-
tein (SPAR) in the hippocampus and cortex (Figure 1K and 
Figure S1F, Supporting Information) in igfbp2−/− mice at 
postnatal day (p)15 and p45. Meanwhile, in the cortex and 
hippocampus of wild-type mice, Golgi staining revealed 
that neuronal dendrites were more richly branched than in 
igfbp2−/− mice (Figure 1L–O). Thus, IGFBP2 is important for 
hippocampal development.
2.2. IGFBP2 Enhances Excitatory Synaptic Transmission
Electrical activity is a characteristic of neuronal development, 
neural circuit maturation, and activity-dependent cognition, 
particularly in the postnatal period.[10] To investigate whether 
IGFBP2 can alter the efficacy of synaptic transmission, we 
maintained slices of mouse hippocampus (p14-17) in vitro and 
exposed them to IGFBP2 while recording the electrical activity 
of pyramidal neurons in the CA1 region. IGFBP2 increased the 
frequency and amplitude of both miniature excitatory postsyn-
aptic currents (mEPSCs) and miniature inhibitory postsynaptic 
currents (mIPSCs) (Figure 2A,B), indicating enhanced release 
of both excitatory and inhibitory neurotransmitters.
IGFBP2 induced a significant increase spike activity of 
pyramidal neurons with a decreased interspike interval when 
depolarized with a series of 500 ms step currents. The latency 
of evoked spikes was reduced (Figure 2C–G) through a reduc-
tion in spike threshold and an increased normalized slope of 
initiation (Figure 2H–J). During IGFBP2-enhanced spiking, 
there was no change in the amplitude or half-width of spikes, 
in the post-spike after hyperpolarization, or in the resting mem-
brane potential (RMP) (Figure S2A, Supporting Information).
This IGFBP2-enhanced excitability could be due to either 
the activation of excitatory inputs or the suppression of inhibi-
tory inputs. Dividing the increase in firing rate (11.8 spikes/s/
neuron, Figure 2G) by the increase in mEPSC frequency 
(2.2 Hz per neuron, Figure 2A) revealed that each pyram-
idal neuron received ≈5.3 excitatory inputs for each spike. 
However, IGFBP2 had no significant effect on the firing rate 
of fast-spiking interneurons in CA1 (FSIs) or regular-spiking 
interneurons (RSIs) (Figure 2K and Figure S2B–D, Sup-
porting Information), and had no significant effect on their 
voltage threshold (Figure S2E,F, Supporting Information). 
Thus, IGFBP2 activates excitatory synapses on pyramidal neu-
rons without affecting inhibitory inputs from FSIs and RSIs. 
Treatment with an IGFR1 antagonist (IGFR1A) prevented this 
enhancement (Figure S2G,H, Supporting Information). Treat-
ment with IGFR1A alone reduced the frequency and amplitude 
of sEPSCs (Figure S3I, Supporting Information), suggesting 
that endogenous IGFBP2 regulates excitatory transmission to 
pyramidal neurons via IGFR1.
To investigate whether IGFBP2 affects the fidelity of spike 
transmission, we made cell-attached and whole-cell current-
clamp recordings from pyramidal neurons and evoked spikes 
synaptically by stimulating Schaffer collaterals (SCs). IGFBP2 
significantly increased the number of spikes evoked by SC 
stimulation while decreasing the spike latency (Figure 3A–D), 
accompanied by enhanced spontaneous spiking (Figure 3E–I). 
Similar results were found in whole-cell recordings for evoked 
(Figure 3J–L) and spontaneous spiking (Figure 3M), and 
were accompanied by enhanced spontaneous and evoked 
EPSPs (Figure 3N,O). Thus IGFBP2-evoked excitation reflects 
enhanced EPSP-spike coupling. In the presence of IGFBP2, 
the γ-aminobutyric acid (GABA) receptor antagonist picro-
toxin (PTX) enhanced both spontaneous and evoked spiking 
of pyramidal neurons that were abolished by the glutamate 
receptor antagonist 7-dinitroquinoxaline-2,3-dione (DNQX). 
Thus, IGFBP2-activation occurred in the continued presence of 
GABAergic inhibition, either from “bilingual” pyramidal neu-
rons that use both GABA and glutamate as neurotransmitters[11] 
or from interneurons.
Since neuronal firing results from the balance between syn-
aptic excitation and inhibition, we investigated the effect of 
IGFBP2 on this balance. We found that IGFBP2 enhanced the 
evoked eEPSCs but not the eIPSCs (Figure 3P–S), and then 
investigated how IGFBP2 enhanced the eEPSCs. IGFBP2 had 
no significant effect on the paired-pulse ratios (PPRs) of either 
EPSCs or IPSCs (Figure S3A,B, Supporting Information), sug-
gesting that it did not affect presynaptic function. Alternatively, 
IGFBP2 may have increased the number of functional synapses. 
One way of measuring the relationship between EPSCs and the 
underlying quantal synaptic responses is with the coefficient 
of variation (CV) of EPSC amplitude, since 1/CV2 is correlated 
with the probability of release. We found an increase in 1/CV2 
for eEPSCs with IGFBP2 and a concomitant decrease in 1/CV2 
for eIPSCs (Figure S3C, Supporting Information).
In the presence of IGFBP2, the 1/CV2 of eEPSCs was 
positively correlated with both the eEPSC amplitude and excita-
tion/inhibition (E/I) ratio, while the 1/CV2 of eIPSCs showed 
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Figure 1. Distribution of IGFBP2-positive cells and total cell counts and morphology in the hippocampus of wild-type and mutant mice. A–E) IGFBP2 
neurons and astrocytes in the hippocampus of wild-type mice (igfbp2+/+). Arrows in B, neurons expressing IGFBP2 and NeuN; open arrows in C, small 
neurons expressing GAD67 and IGFBP2; solid arrows, larger neurons expressing GAD67 without IGFBP2, D) Astrocytes expressing IGFBP2, E) Neurons 
expressing IGFBP2 in wild-type and not in igfbp2−/− mice. F) DAPI staining in the hippocampus of wild-type and igfbp2−/− mice. G,H) Staining with 
DAPI, NeuN, and GAD67 in CA1 from wild-type and igfbp2−/− mice at p15 and p45. I,J) Quantification of total cell number and optical density in the 
stratum oriens (SO), stratum pyramidale (SP), and stratum radiatum (SR) of CA1, CA3, and the DG (n = 4 mice). K) Expression of IGFBP2, NR2B, 
and SPAR. L–O) Golgi-stained neurons in cortex and hippocampus. K) *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed t-tests and Bonferroni’s multiple 
comparison. Data are mean ± SEM. Scale bar, 20 µm in A–E, G, H; 200 µm in F, N, O; 500 µm in L, M (50 µm, inset).
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Figure 2. Excitatory and inhibitory responses and excitability of p14-17 CA1-pyramidal neurons to IGFBP2. A,B) Exemplar mEPSCs/mIPSCs in pyramidal 
neurons at –70 mV and the cumulative distributions of their frequency and amplitude (DNQX, AP5, and TTX added in incubation. n = 11 EPSCs, 
12 IPSCs, 4-6 washouts. C–G) Exemplar spikes, cumulative probability, plots of interspike interval, spike latency, and pyramidal neuron excitability (n = 8). 
H–J) Voltage threshold (n = 19), threshold current (n = 8), and normalized slope of initiation for spikes (n = 8). K) CA1-FSI excitability (n = 5). Two-
sample Kolmogorov-Smirnov test in panels A, B, and D; otherwise, paired two-tailed t-tests. * P < 0.05, ** P < 0.01, ***P < 0.001; data are mean ± SEM.
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no such correlation (Figure S3D–G, Supporting Informa-
tion). No correlation was found between the PPR of EPSCs 
and the eEPSC amplitude either in the presence or absence 
of IGFBP2, while the negative correlation between the PPR of 
IPSCs and the eIPSC amplitude was weaker in the presence of 
IGFBP2 (from p = 0.01 to p = 0.04) (Figure S3H,I, Supporting 
Information), suggesting that IGFBP2 might be involved 
in use-dependent depression of IPSCs.[12] Since GABAe-
rgic synapses express bidirectional plasticity in the neonatal 
hippocampus,[13,14] it appears that IGFBP2 may increase functional 
excitatory synapses with a concomitant decrease or no reduction 
of GABAergic synapses (Figure S3J, Supporting Information).
To learn how the interaction between EPSCs and IPSCs 
determines the final synaptic signal, we configured whole-cell 
voltage-clamp recording at −40 mV for EPSCs, 0 mV for IPSCs, 
or −80 mV to record both currents from the same cells. IGFBP2 
significantly increased both the frequency and amplitude of 
sEPSCs (confirmed by blocking with DNQX) and postsynaptic 
currents (PSCs; the sum of EPSCs and IPSCs), but not those of 
sIPSCs (Figure S4A–C, Supporting Information). In the presence 
of IGFBP2, the PSC frequencies became correlated with EPSC 
but not IPSC frequencies (Figure S4D,E, Supporting Informa-
tion). We obtained the same results for spontaneous amplitudes 
(Figure S4F,G, Supporting Information). Thus, in the presence 
of IGFBP2, increased EPSCs enhance the excitation–inhibition 
(E/I) ratio (Figure S4H,I, Supporting Information).
2.3. IGFBP2 Increases in the E/I Ratio Are Cell-Type Specific
To gain an overview of synaptic potentiation, we recorded 
evoked as well as spontaneous activity from the same cells. 
We found that there are two different responses to IGFBP2 
in electrophysiologically different pyramidal neurons in CA1. 
In pyramidal neurons that displayed lower frequencies of 
either sEPSCs or sIPSCs [≈1 Hz; termed “L-cells”], IGFBP2 
enhanced the eEPSC but had no significant effect on the 
eIPSCs (Figure 4A–C, Figure S5A,B, Supporting Informa-
tion). By contrast, in cells with higher spontaneous activity 
[≥2±0.5 Hz; termed “H-cells”]; Figure 4D–F and Figure S5C, 
Supporting Information), IGFBP2 reduced both the eEPSCs 
and the eIPSCs (Figure 4G,H). Thus IGFBP2 has cell-type 
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Figure 4. IGFBP2 coordinates L and H cells plasticity in a cell-type specific manner. A–C) Exemplar recordings from CA1 pyramidal L cells with eEPSC 
and eIPSC amplitude (n = 8). D,E) Comparison of spontaneous activity in L and H cells. F–H) Exemplar recordings from CA1 pyramidal H cells with 
eEPSCs and eIPSCs (n = 6). I) Comparison of eE/I and sE/I in L and H cells (n = 6). J,K) Exemplar IPSCs (upper) and EPSCs (lower) evoked by 60 Hz 
stimulation and cumulative E/I ratios (n = 10). L) Exemplar simultaneous recording of sEPSCs, sIPSCs, and action potentials. M) IGFBP2 enhanced 
excitation (n = 7). Paired two-tailed t-test except panels D and E. *P < 0.05, **P < 0.01; data are mean ± SEM.
Figure 3. IGFBP2 enhances the fidelity of spike transmission. A) Exemplar cell-attached spikes (CA1 pyramidal neurons) evoked by SC stimulation. 
B–D) Spike number, spike probability (n = 19), and spike latency (n = 11) after IGFBP2 treatment. E–I) Exemplar cell-attached spontaneous spiking 
under current-clamp (n = 7) and voltage-clamp (n = 8). J–M) Exemplar whole-cell spikes evoked by SC stimulation with spike probability (n = 9), spike 
latency (n = 6), and spontaneous spike probability (n = 5). N,O) Exemplar traces and group data of s/eEPSPs (n = 4, 9) by SC stimulation. P–S) Exemplar 
eIPSCs and eEPSCs evoked by SC stimulation. IGFBP2 enhanced eEPSCs without affecting eIPSCs, and increased the E/I ratio (n = 15). Two-sample 
Kolmogorov-Smirnov test in panel O; paired two-tailed t-tests elsewhere. *P < 0.05, **P < 0.01; data are mean ± SEM.
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specific effects and L cells are the principal target of the ele-
vated E/I ratio (Figure 4I). Neither IGFBP2 nor high-frequency 
stimulation (HFS) significantly increased the sIPSC amplitude 
in either L or H cells (Figure S5B,C, Supporting Information), 
while suppression of the eIPSCs in H cells suggests potentia-
tion and stabilization of excitatory synapses.
We next asked how the plasticity of L and H cells is affected 
by IGFBP2. In the presence of IGFBP2, we found a positive cor-
relation between sEPSC frequency and eEPSC amplitude in L 
cells (Figure S5D, Supporting Information) but not in H cells 
(Figure S5E, Supporting Information). However, there was no 
such correlation for inhibitory synaptic activity (sIPSC vs eIPSC) 
in either L or H cells in either the presence or knockout of 
IGFBP2 (Figure S5F,G, Supporting Information). A positive cor-
relation between eEPSC and eIPSC amplitudes in both L and H 
cells (Figure S5H,I, Supporting Information) indicates that the E/I 
ratios are similar in CA1 pyramidal neurons of both types, while 
the absence of such a correlation in the presence of IGFBP2 in L 
cells (Figure S5H, Supporting Information) and a negative correla-
tion in H cells (Figure S5I, Supporting Information), suggests that 
a shift in the E/I ratio is cell-type specific and IGFBP2 dependent.
During 60 Hz stimulation of the SCs, IGFBP2 increased the 
eEPSC amplitude but not the eIPSC amplitude, resulting in a 
cumulatively enhanced eE/I ratio (Figure 4J,K and Figure S5J, 
Supporting Information). Notably, the stimulus trains evoked a 
nearly homogeneous pattern of EPSC amplitudes (Figure 4J), indi-
cating that activity is unsaturated during development. This was 
confirmed by E–I dynamics with spontaneous firing (Figure 4L,M).
2.4. Interruption of E-I Balance in igfbp2−/− Mice
The frequencies of sEPSCs and sIPSCs were lower in igfbp2−/− 
mice than in wild-type mice with no differences in amplitude 
(Figure 5A1-2, Figure S6A, Supporting Information). Pyram-
idal neurons showed prolonged interspike intervals, a more 
depolarized voltage threshold, and an increased threshold cur-
rent, resulting in decreased spiking and a prolonged spike 
latency (Figure 5B–E and Figure S6B,C, Supporting Informa-
tion). In addition, decreased spontaneous firing was found 
in cell-attached and whole-cell recordings in both voltage- and 
current-clamp modes (Figure 5F and Figure S6D, Supporting 
Information) and sEPSP amplitudes were decreased (Figure 5G). 
Exogenous IGFBP2 (500 × 10−9 m)[15] rescued these changes as 
well as the excitability of the pyramidal neurons (Figure S7A–C, 
Supporting Information), suggesting that it plays a crucial role 
in synaptic homeostasis and excitability. There were no signifi-
cant differences in spike shape, resting membrane potential or 
membrane input resistance (RIn) between control and igfbp2−/− 
mice (Figure S6E, Supporting Information).
Adv. Sci. 2019, 6, 1901152
Figure 5. IGFBP2 maintains the E–I balance in igfbp2−/− mice. A) Exemplar CA1 pyramidal neuron A1) sEPSCs, A2) sIPSCs, A3) PSCs, A4) eEPSCs–
eIPSCs, and A5) EPSCs evoked by 60 Hz stimulation. Slices from p14-17 mice. B) Exemplar spikes from pyramidal neurons and FSIs in igfbp2+/+ (Ctrl) 
and igfbp2−/− (KO) mice. C) Cumulative probability for interspike intervals (ms) among different groups. D,E) Changes in the voltage threshold and 
threshold current (n = 12). F,G) Exemplar spikes (upper: whole-cell; middle: cell-attached) and cell-attached sEPSPs (n = 12). H) The E/I ratio was 
restored after IGFB2 treatment. I,J) Exemplar EPSCs and IPSCs evoked by 60 Hz stimulation and cumulative E/I ratios (n = 18). Paired two-tailed t-test 
in panels D, E, G, H, J. * P < 0.05, ** P < 0.01; data are mean ± SEM.
www.advancedsciencenews.com
1901152 (8 of 14) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedscience.com
The correlation between excitatory and inhibitory inputs 
onto pyramidal neurons was interrupted in igfbp2−/− mice and 
rescued after IGFBP2 treatment for 20 min (Figure S7A,B, 
Supporting Information). Normalized EPSC- and PSC-fre-
quencies and amplitudes in neurons from either wild-type or 
igfbp2−/− mice were positively correlated after IGFBP2, while 
IPSC and PSC frequencies and amplitudes were positively 
correlated in wild-type but not in igfbp2−/− mice and were less 
strongly correlated in wild-type mice after IGFBP2 treatment 
(Figures S4D,F and S7C,D, Supporting Information). Neither 
sEPSCs nor sIPSCs were correlated with spiking in igfbp2−/− 
mice. After IGFBP2 treatment only sEPSCs but not sIPSCs 
were correlated with spiking (Figure S7E,F, Supporting Infor-
mation), suggesting that increased excitatory inputs con-
trol the spiking of CA1 pyramidal neurons in the presence 
of IGFBP2. The reduced eE/eI and sE/sI-frequency but not 
the sE/I- amplitude was rescued after IGFBP2 treatment in 
igfbp2−/− neurons due to enhanced excitation (Figure 5A4,H and 
Figure S7G–J, Supporting Information).
In response to high-frequency (60 Hz) stimulation, pyram-
idal neurons in igfbp2−/− mice showed a shallower train of 
EPSC amplitudes (Figure 5I) than in wild-type mice (Figure 5J) 
that was rescued by IGFBP2 (Figure S7K,L, Supporting 
Information) with no effect on cumulative IPSC amplitudes 
(Figure S7M,N, Supporting Information). Thus IGFBP2 
restored the E/I ratios (Figure 5J and Figure S7O, Supporting 
Information). The last few EPSCs of the train were larger than 
the first few (Figure 5I), while IPSCs showed the converse 
pattern. After IGFBP2 treatment we found two types of rescued 
patterns of EPSC amplitudes: either the first few EPSCs in the 
train were smaller (Figure 5A5) or the first few EPSCs were 
larger (Figure 5I), further suggesting that IGFBP2 regulates 
synaptic function in a cell-type-specific manner.
2.5. IGFBP2 Regulates LTP and Water Maze Learning and 
Memory
We then asked how IGFBP2 affects Hebbian plasticity in L 
cells in slices from neonatal wild-type mice. In the presence 
of IGFBP2, HFS elicited stronger LTP in CA1 pyramidal neu-
rons (200.9 ± 3.9%) than in controls (vehicle, 156.7±4.2%), 
while treatment with mutant-IGFBP2[15] had no effect 
(155.2 ± 3.9%) (Figure 6A,B). In slices from igfbp2−/− mice, HFS 
induced a transient synaptic potentiation (133.9 ± 3.1%), while 
IGFBP2 elicited a large initial potentiation with poorly main-
tained LTP magnitude (185.1 ± 7.4%, Figure 6C). IGFR1A sup-
pressed the IGFBP2-induced LTP (158.8 ± 4.3%, Figure 6D,E). 
IGFBP2 induced no LTP at GABAergic synapses (data not 
shown). IGFBP2 significantly increased the frequency and 
amplitude of spontaneous NMDA-mediated EPSCs with a con-
comitant increase in NMDA-mediated EPSCs evoked by SC 
stimulation that was blocked by the NMDA receptor antago-
nist APV (25 × 10−6 m) (Figure 6F–I). Since IGFBP2 increased 
both NMDA and AMPA (α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid) currents (Figure 6J), NMDA/AMPA 
ratios were preserved (Figure 6K) following activity-dependent 
synaptic scaling. No significant differences were found in the 
field PPR in CA1 pyramidal neurons between wild-type and 
igfbp2−/− mice before and after HFS, either in the presence or 
absence of IGFBP2 (Figure 6L,M).
When we assessed hippocampus-dependent learning and 
memory in the Morris water maze at p45 and p60, igfbp2−/− 
mice showed a slower learning profile (F(1,72) = 11.15, P < 0.05) 
than wild-type mice. In memory-retention tests, they also 
spent less time exploring the former location of the platform 
(Figure 6N,O). A similarly poor performance with a decreased 
PSD-95 was seen in wild-type mice microinjected with IGFBP2 
antibody through cannulae implanted bilaterally in the hip-
pocampus (Figure 6P,Q and Figure S8A, Supporting Informa-
tion). Similar escape latencies and swimming speeds during 
training and retention trials in control IgG and IGFBP2 anti-
body-treated mice revealed that the impaired performance of 
the latter mice was not due to deficits in vision or motor activity 
(data not shown). These results indicate that IGFBP2 is specifi-
cally involved in learning and memory.
Examination of the impact on synaptic morphology 
in cultured hippocampal neurons showed that IGFBP2 
(500 × 10−9 m) induced an increase in total neurite length and 
numbers of primary dendrites and secondary branch points 
per neuron after 3 d (n = 105, Figure 6R–U). The early induc-
tion of dendritic spines in ≈5% of neurons (Figure 6R, inset) 
suggests that IGFBP2 increases the number of synapses. No 
changes in hippocampal IGF1 and IGF2 levels were seen in 
response to microinjection of IGFBP2 in WT and KO mice 
(Figure S8B,C, Supporting Information). Interestingly, 
corticotrophin-releasing factor (CRF, 0.1 × 10−9 m), increased 
IGFBP2 release via CRFR1 receptors in cultured hippocampal 
neurons and igfbp2−/− mice had lower levels of CRF mRNA 
in the hippocampus (Figure S9A,B, Supporting Information). 
Intermittent hypoxia (16% O2) enhanced IGFBP2, IGFR1, 
CRF, and CRFR1 expression in the neonatal hippocampus 
(Figure S9C–E, Supporting Information). IGFR1 was enriched 
in dendritic spines/filopodia and boutons and colocalized with 
CRFR1 in cultured hippocampal neurons (Figure S9F, Sup-
porting Information). At 12.5 × 10−9 m (but not 50 × 10−9 or 
25 × 10−9 m), CRF-induced robust LTP (183.8 ± 8.9%) was sup-
pressed by IGFR1A (143.3 ± 3.6%), to a level similar to that of 
the effect on LTP amplitude in the presence of IGFR1A alone 
(148.5 ± 4.2%) (Figure S9G–L, Supporting Information). The 
response to a CRFR1 antagonist was similar in the presence 
of IGFBP2 (127.3 ± 6.6%). Thus there is cross-talk between 
CRFR1 and IGFR1.
3. Discussion
The IGFBP2-knockout (KO) (IGFBP2−/−) and wild-type 
(IGFBP2+/+) mice in our study were healthy and fertile and had 
similar body weights at birth and p45–p60; furthermore, HE 
staining of the hippocampus showed no significant difference 
between the KO and wild-type groups, consistent with previous 
findings.[16] However, the Morris water maze performance of 
wild-type mice was better than for KO mice at p45 and p60.
Our study confirms IGFBP2 expression by pyramidal 
neurons, GABAergic interneurons, and astrocytes in the 
hippocampus and cortex of the developing mouse brain.[17] 
The distribution of IGFBP2-positive cells in the hippocampus 
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suggests that IGFBP2 acts there by an autocrine and/or parac-
rine mechanism to influence synaptic activity and learning and 
memory. As neonates grew, the number of IGFBP2-positive 
neurons increased as did the mRNA levels of IGFBP2, SPAR, 
and NR2B; hippocampal IGFBP2 protein increased gradually 
from p14 to p35, along with PSD-95 and SPAR proteins. SPAR 
localizes in dendritic spines and forms a complex with PSD-95 
and NMDAR.[18] In contrast, igfbp2−/− mice had diminished 
levels of SPAR mRNA and NR2B mRNA and reduced numbers 
of hippocampal cells and interneurons, indicating involvement 
of IGFBP2 in NMDAR-dependent learning and memory via 
alteration of dendritic spines as reported for IGF-II.[1] IGFBP2 
is also involved in brain disorders as well as cognitive functions. 
The numbers of IGFBP2-positive cells decreased in the hip-
pocampus of a mouse model of amyotrophic lateral sclerosis, 
and serum IGFBP2 levels were lowered in patients with bipolar 
disease and depression.[2] IGFBP2 plays a key role in neurite 
outgrowth and the early induction of spines, as well as SPAR 
cytoskeletal construction and NR2B expression. Thus, IGFBP2 
is synthesized and released in the hippocampus and is impor-
tant for the development of axons and dendritic spines[19,20] and 
in learning and memory.
IGFBP2 is required for E-I balance in a cell-type-specific 
manner. We found that IGFBP2 enhanced both the evoked 
and spontaneous neuronal excitability and the fidelity of 
spike transmission of CA1 pyramidal neurons by ≈5.3 excita-
tory inputs. CA1 pyramidal neurons containing IGFBP2 
may also enable parallel information processing[21] in cell-
type-specific firing patterns[22] since we found IGFBP2 did 
not interfere with CA1-interneuron spiking. IGFBP2-pos-
itive neurons are a subpopulation in the hippocampus and 
IGFBP2 may be a new neuromodulator at the hippocampal 
microcircuit level.
Synaptic strength results from the integration of excita-
tory and inhibitory synaptic inputs. Here we demonstrated 
that IGFBP2 enhanced both mEPSCs and mIPSCs, revealing 
bidirectional homeostatic scaling. On the other hand, IGFBP2 
selectively enhanced sEPSCs while sparing sIPSCs in the pres-
ence of action potentials. Taken together, on a competitive 
basis IGFBP2 showed a selective bias toward excitatory rather 
than inhibitory input by simultaneous upregulation of evoked 
and spontaneous excitatory synaptic input via an overlapping 
or independent mechanism.[23] Interestingly, igfbp2−/− mice 
manifested not only a drop in sEPSC frequency but also in 
sIPSCs and this was rescued after IGFBP2 treatment, con-
sistent with the idea that neurons maintain the E-I balance by 
autonomously decreasing their inhibitory inputs in response to 
excitatory synaptic dysfunction.[24] We found that IGFBP2 also 
enhanced evoked synaptic excitation in pyramidal neurons of 
the hippocampus. The excitation of pyramidal neurons was 
diminished in igfbp2−/− mice and was rescued by application 
of IGFBP2 for 20 min, indicating that IGFBP2 can stabilize 
nascent synapses.[25] Binding of IGFBP2 to IGFR1 induces a 
transient increase in intracellular calcium concentration[5] that 
may be responsible for synaptic stability. Thus, IGFBP2, as a 
member of a growth factor family, performs a significant regu-
latory role in synapses.
Using electrophysiological techniques, we identified a previ-
ously unrecognized pyramidal cell-type in the CA1 region with 
distinct neurophysiological properties in response to IGFBP2. 
Among the pyramidal neurons, IGFBP2 preferentially excited 
L cells rather than H cells. Corelease of glutamate and GABA 
in the presence of IGFBP2 may be responsible for shunting 
inhibitory currents, facilitating excitation by cell-type-specific 
orchestration of the electrical properties of pyramidal neurons. 
This process can contribute to the activity-dependent modula-
tion of synaptic connectivity that is important for hippocampal 
development. IGFBP2 may assist in the redistribution of excita-
tory and inhibitory activity between the two types of pyramidal 
neurons during spatial learning.[21,22]
IGFBP2 enhanced mEPSC frequency without changing the 
PPR, indicating a novel role of IGFBP2 in glutamate receptor 
kinetics.[26,27] Since inhibitory synapses can be unstable during 
development,[13] enhancement of mIPSCs by IGFBP2 can 
allow neurons to stabilize activity without changing the relative 
strength of synaptic inputs. Studies of igfbp2−/− mice revealed 
that IGFBP2 regulated the E-I balance during early life. We 
noted a ≈50% reduction of E/I-ratios in igfbp2−/− compared to 
controls that was rescued after IGFBP2 treatment, indicating 
that IGFBP2 enhances information transmission and E–I 
dynamics. Despite the complexity of the distribution of E/I 
ratios, these data are consistent with the notion that activity 
remains unsaturated during development. Furthermore, 
FSIs inhibit somatostatin-expressing interneurons to regu-
late the output of pyramidal neurons,[28] so excitation of FSIs 
by IGFBP2 may alter interneuronal–pyramidal neuron con-
nections. Thus IGFBP2 enhanced excitatory transmission and 
increased the E-I balance in a cell-type specific manner in the 
hippocampus.
IGFBP2 regulates LTP via IGFR1 signaling and crosstalk 
with CRFR. IGFBP2 increased the number of functional syn-
apses and enhanced LTP by activating both spontaneous and 
evoked AMPAR and NMDAR currents via an IGFR1 signaling 
pathway. Impaired LTP and poor performance in the water 
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Figure 6. Mechanism of IGFBP2-mediated LTP enhancement. A,B) IGFBP2 facilitated LTP (n = 10) but mutant IGFBP2 did not (n = 8). C) LTP in 
igfbp2−/− slices was rescued by IGFBP2 treatment (n = 10). D) IGFBP2 failed to maintain stable LTP in IGFR1A-treated igfbp2+/+ slices (n = 6). E) Com-
parison of LTP magnitudes (ANOVA). F–I) Exemplar s/eNMDAR currents in CA1 pyramidal neurons at +40 mV from SC stimulation, and cumulative 
distribution of frequency G and spontaneous H (n = 11), or evoked amplitudes I (n = 7). J) Exemplar eNMDAR and eAMPAR currents. K,L) Exemplar 
traces of field EPSPs evoked at 50 ms intervals and field PPR (n = 11) after IGFBP2 treatment in igfbp2+/+ and igfbp2−/−slices. M) Normalized NMDA 
(n = 7) and AMPA (n = 13) currents and NMDA/AMPA ratios. N,O) Escape latency (F(1,72) = 11.15, P < 0.05) and time spent in each quadrant (p45 
and p60), and representative movement traces at p45 (n = 10). P,Q) Longer escape latency in the training phase and less time around the platform 
in probe tests in mice injected with IGFBP2 antibody (control, IgG = 7; IGFBP2 antibody = 8); and absence of significant differences between IgG and 
IGFBP2 antibody-injected mice in the latency of visual tests and swimming speed (data not shown). R) Representative cultured hippocampal neurons 
and dendritic spines (insets). S–U) Neurite length, and numbers of primary neurites and branch points, after IGFBP2 treatment (n = 105). One-way 
ANOVA with Bonferroni’s correction in panels O and P, two-tailed t-test. *P < 0.05, **P < 0.01, ***P < 0.001; data are mean ± SEM. Scale bars, 20 µm 
in R (5 µm, inset).
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maze by igfbp2−/− mice confirmed the involvement of IGFBP2 
in spatial learning and memory.
Our results support an emerging role of IGFBP2 as a key 
associative signal with the stress hormone CRF driving activity-
dependent plasticity to flexibly tune neural circuits. The rela-
tionship between stress and synaptic plasticity takes the form 
of an inverted-U, and the hippocampus is necessary for the 
enhancement and impairment of learning after stress.[29] Mean-
while, hippocampal IGFBP2 and IGFR1 protein increased 
gradually from p28 to p35 in mice and was enhanced further 
after the mild postnatal stress of intermittent hypoxia. Persis-
tent increases in SPAR expression as well as LTP were reported 
in mice exposed to intermittent hypoxia in a previous study 
from our lab. Deletion of insulin receptor and IGFR1 in mice 
hippocampus decreased expression of glutamate receptor 
1 protein in synaptosomes, impaired cognition, and increased 
anxiety behaviors.[30] Together, these findings suggest that 
there is cross-talk between stressors and learning and memory 
during early life. Experiments on a rat model of post-traumatic 
stress have also proposed that IGFBP2 has a therapeutic-like 
antidepression effect.[31] Microarray analysis showed mark-
edly increased-IGFBP2 mRNA in α-secretase cleaved amyloid 
precursor protein (a neuroprotective)-treated organotypic hip-
pocampus slice culture.[32] Consistently, using the hippocampal 
transcriptome and RT-PCR, robust activation of hippocampal 
IGFBP2 in a middle-aged female rat model of menopause with 
estradiol replacement has shown that Igfbp2 contributes to neu-
rogenesis, neuroplasticity, and memory.[33] Thus, IGFBP2 is a 
potential target for learning and memory impairment therapies 
and also for the treatment of neurodegenerative diseases.
4. Conclusions
In summary, we found that IGFBP2 enhances excitatory inputs 
onto CA1 pyramidal neurons, facilitating their intrinsic excit-
ability and spike transmission, and regulates plasticity at excita-
tory synapses in a cell-type specific manner. It contributes to 
LTP facilitation by enhancing spontaneous and evoked NMDAR 
excitatory postsynaptic currents by enhancing neurite prolifera-
tion and elongation. Knockout of igfbp2 leads to reduced num-
bers of pyramidal cells and interneurons, which impairs LTP 
and cognitive performance and reduces the tonic excitation 
of pyramidal neurons, all of which are rescued by addition of 
IGFBP2. Our results provide a novel insight into the role of 
IGFBP2 in cognition during early life.
5. Experimental Section
Animals: Wild-type C57BL/6J mice (certification no. SCXK2008-0033) 
were purchased from the Experimental Animal Centre of Zhejiang 
Province (China) and group housed under a 12/12-h light/dark cycle 
(lights on 06:00-18:00) at 20 ± 2 °C with free access to food and water 
for one week prior to experiments. All animal procedures complied 
with the National Institutes of Health guidelines using protocols 
approved by the Institutional Animal Care and Use Committee of 
Zhejiang University (ZJU201304-1-01-025). Mutant igfbp2−/− mice on 
the C57BL/6J genomic background (MGI: 96437) were purchased from 
UC Davis (B6;129S5-igfbp2Gt(OST365171)Lex/Mmucd, mmrrc:011721-UCD) 
and F2 and F3 generations were used according to institutional 
guidelines. Genotyping was performed by PCR with genomic DNA 
extracted from tail tips. Primers used for igfbp2−/− genotyping 
were: for mutant forward: 5′-GGGTTCTCCTGGCTGGTGACTC-3′; 
reverse: 5′-ATAAACCCTCTTGCAGTTGCATC-3′; and wild-
type forward: 5′-GGGTTCTCCTGGCTGGTGACTC-3′; reverse: 
5′-GAGTCTCCCTGGATCTGA TTAAGG-3′.
Electrophysiology: Male wild-type C57BL/6J mice at p14-17 were 
anesthetized by isoflurane inhalation or with 90 mg kg−1 sodium 
pentobarbital before decapitation. The brain was extracted and the 
left hippocampus was dissected out and glued to the platform of a 
semiautomatic vibrating-blade microtome (VT1000; Leica). The platform 
was then placed in a slicing chamber containing artificial cerebrospinal 
fluid (aCSF) at 4 °C. Hippocampal slices (350 µm) were prepared in ice-
cold aCSF consisting of (in × 10−3 m) 125 NaCl, 3 KCl, 1.25 NaH2PO4, 
2 MgSO4, 2 CaCl2, 25 NaHCO3, 15 glucose and 0.4 l-ascorbic acid. All 
slices were incubated in a custom-made interface holding chamber 
submerged in aCSF at 34 °C for 1 h and then maintained at 27 °C for 
up to 8 h until they were transferred to the recording chamber. Slices 
were superfused with aCSF at 29–31 °C (2 mL min−1 for whole-cell and 
3 mL min−1 for extracellular recording). All solutions were saturated with 
95% O2 and 5% CO2.
Whole-Cell Recording: Slices were visualized through an infrared-
sensitive CCD camera with a 40 × water-immersion lens (Olympus) 
and recorded using whole-cell techniques (MultiClamp 700B Amplifier, 
Digidata 1440A analog-to-digital converter) and pClamp 10.2 software 
(Axon Instruments/Molecular Devices). Slices were allowed 10–30 min 
to equilibrate before recording. Recording electrodes were pulled on a 
horizontal puller (Sutter P-1000). For whole-cell recordings, the access 
resistance was monitored by a hyperpolarizing step of –5 mV every 
60 s; experiments were discarded if the series resistance exceeded 20%. 
Miniature EPSCs and sEPSCs were recorded from pyramidal neurons in 
voltage-clamp using glass pipettes with a tip resistance of 2–4 MΩ and 
an internal solution containing (in × 10−3 m) 130 K gluconate, 20 KCl, 
10 HEPES buffer, 4 Mg-ATP, 0.3 Na-GTP, 10 disodium phosphocreatine, 
and 0.2 EGTA, pH 7.3 with KOH, and 288 mOsm. Gabazine 
(10 × 10−6 m), DNQX (10 × 10−6 m), TTX (100 × 10−9 m), and IGFBP2 
(1 × 10−6 m) were delivered in the bathing solution during recordings. 
For mIPSC recording, we used a high Cl− internal solution containing 
(in × 10−3 m) 130 CsCl, 4 NaCl, 10 TEA-Cl, 10 HEPES, 0.2 EGTA, 10 Tris-
phosphocreatine, 4 Mg-ATP and 0.5 Na-GTP, pH 7.3 with CsOH, and 
288 mOsm. Recordings of sEPSCs, sIPSCs, PSCs from the same neuron 
were based on reversal potentials as described previously.[12] The 
holding potential for sEPSC = −40 mV, sIPSC = 0 mV, and PSC = −80 mV. 
No antagonists were added to the bath in these experiments, except for 
EPSCs that were confirmed by DNQX exposure at the end of recordings. 
Spontaneous frequency and peak amplitude were measured with the 
Mini Analysis program (Synaptosoft).[34]
Action Potential Recording: For whole-cell-evoked action potential 
recording either by current injection or SC stimulation, glass pipettes 
(2–4 MΩ) were filled with a solution containing (in × 10−3 m) 
130 K gluconate, 20 KCl, 10 HEPES buffer, 4 Mg-ATP, 0.3 Na-GTP, 
10 disodium phosphocreatine and 0.2 EGTA, pH 7.2 with KOH, and 
288 mOsm. The inter-spike intervals (ISI), calculated for averaged 
intervals between sequential action potentials in a train elicited in 
response to a 500 ms suprathreshold current of 50 to 250 pA, were used 
to quantify the excitability of CA1 pyramidal neurons and FSIs. Shape 
parameters were measured from action potentials evoked by 500 ms 
current injection. The action potential threshold was measured as the 
minimal membrane potential value at the time corresponding to the 
peak of the third derivative of the membrane potential, as described 
previously,[34] using custom routines written in the Mini Analysis 
program (Synaptosoft). Offline analysis was performed using custom 
routines written in Clampfit 10.2, Prism 5, and Origin8 pro.
Same-Cell eEPSCs, eIPSCs, and PPR Recording: During same-cell 
recording of eEPSCs, eIPSCs, and PPR, the same pipette solution was 
used as for m/sEPSC recording, in which K gluconate and KCl were 
replaced by CsMeSO3 and CsCl, respectively. eEPSCs and eIPSCs were 
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recorded at their respective reversal potentials for EPSCs (0/+10 and 
−60 mV).[35] The PPR was determined to estimate release probability. 
The peak amplitudes were evoked by two identical electrical stimuli 
separated by 50 ms and the PPR was calculated as the ratio of the peak 
amplitudes of EPSC-IPSC2/EPSC-IPSC1. 60-84 individual traces were 
recorded to measure the average PPR.
Same-Cell Recording of Action Potentials, s/eEPSCs, s/eIPSCs and PSCs: 
K+-based pipette solution was used for EPSC, IPSC and action potential 
recordings and the holding potential was gradually changed from 
−60 to 0/+10 mv. EPSC/IPSC traces were evoked by 60 Hz stimulation 
(30 stimuli). Four individual traces were averaged to measure cumulative 
EPSC/IPSC amplitudes. After action potential recording in the whole-cell 
current-clamp mode, the MultiClamp 700B Amplifier was switched to the 
voltage-clamp mode and EPSCs/IPSCs were recorded after a minimum 
of 2 min. In the case of cell-attached recording of action potentials, the 
time between current- and voltage-clamp recordings was at least 1 min, 
so that recovery from short-term modification was complete.
Same-Cell Simultaneous Recording of Spontaneous EPSCs, IPSCs, and 
Action Potentials: K+-based pipette solution was used for same-cell 
simultaneous recording of sEPSCs, sIPSCs, and action potentials in 
voltage-clamp mode, with a holding potential at which the amplifier 
current, Iamp = 0 pA.
NMDAR-EPSCs Recording: For s/eNMDAR current recording, the Cs+-
based pipette solution was used. s/eNMDAR EPSCs were recorded at a 
holding potential of +40 mV in the presence of PTX and DNQX. NMDAR 
currents were evoked using a tungsten bipolar electrode placed in the 
SC excitatory afferents from area CA3 to deliver stimuli.
EPSPs: Whole-cell spontaneous and SC-stimulation-evoked EPSPs 
were recorded from CA1 pyramidal neurons using the K+-based pipette 
solution in current-clamp mode. For cell-attached sEPSP recording the 
pipettes were filled with modified aCSF (1.5 × 10−3 m KCl).
Cell-Attached Recording: For cell-attached measurement of 
spontaneous and SC-evoked action potentials, results were pooled from 
recordings in modified aCSF (1.5 × 10−3 m KCl for spontaneous firing; 
1 × 10−3 m CaCl2 and 1 × 10−3 m MgSO4 for evoked spiking).
Extracellular Recording: Field EPSPs were evoked at 0.05 Hz as 
previously described[36] and recorded with an aCSF-filled pipette (1–2 MΩ) 
positioned in the stratum radiatum of CA1; SC inputs were stimulated 
with monophasic pulses using a bipolar concentric electrode placed in 
CA3. LTP was induced by HFS consisting of four 1 s trains of 100 Hz 
pulses, delivered 20 s apart or four trains delivered 5 min apart, with the 
stimulus intensity set at 20–30% of the spike threshold. Field potentials 
were analyzed using Origin8 software.
Cell Culture: Hippocampal neurons were cultured as described 
previously. Briefly, embryonic hippocampal neurons (E18) were 
dissociated in Ca2+- and Mg2+-free Hank’s balanced salt solution 
containing 0.125% tyrosine and triturated in Dulbecco’s modified 
Eagle’s medium (DMEM)/10% fetal bovine serum (FBS), and plated 
on poly-d-lysine-coated 60 mm dishes at 1 000 000 cells per well. 
Cultures were grown in serum-free medium for 21 d before being used 
for biochemical experiments and the medium was changed every 5 d. 
Dendritic morphology was studied in cultures of 2500 cells per coverslip 
grown for only 5 d and for 14–18 d. IGFBP2 (500 × 10−9 m, 3 d) was 
directly applied to cultured neurons and saline was added as control.
Immunocytochemistry and Neurite Morphology Analysis: Cultured 
hippocampal neurons at 3 d in vitro were treated with IGFBP2 and grown 
for an additional 5 d for neurite analysis. Cells were fixed for 10 min in 
ice-cold 4% paraformaldehyde, permeabilized with 0.2% Triton-X-100 
in phosphate-buffered saline (PBS), and blocked with 5% BSA (bovine 
serum albumin) for 1 h. Subsequently, cells were incubated with primary 
rabbit antibody to MAP2 (1:1,000, Millipore) in 5% BSA for 3 h at 
room temperature. Coverslips were washed three times with washing 
buffer (0.05% Triton-X-100 in PBS) for 10 min each, incubated with 
secondary antibodies conjugated with Alexa Fluor 488 and 555 (1:1000, 
Invitrogen, Carlsbad, CA) in 5% BSA for 1 h at room temperature, and 
washed three times with washing buffer for 10 min each. Coverslips 
were mounted in Fluoroshield mounting medium containing 4, 
6-diamidino-2-phenylindole (DAPI) (Sigma). Images were acquired 
with a 60× oil-immersion objective (NA 1.4) on an inverted confocal 
microscope (Olympus FV1000) by investigators blind to the experimental 
condition. Three parameters of neurite growth were analyzed using 
MetaMorph image analysis software, after capturing images of MAP2-
positive neurons with cell body diameters of 15-20 µm: total length of 
neurite (µm), number of primary neurites and number of branch points 
per cell. Application settings were adjusted at the beginning of analysis 
and kept the same for all images in the experiment. Images of 15–20 
neurons per condition were captured in six independent experiments. 
The following primary antibodies were used: anti-IGFR1 antibody (1:500, 
Milliopre-MABS192)/rabbit anti-IGFR1 (1:200, Sigma) and anti-CRFR1 
(1:200, R&D SYSTEM-MAB3930); colocalization was determined using 
FV10-ASW 4.1 Viewer software.
Immunohistochemistry: Mice were anesthetized by intraperitoneal 
injection of ketamine (100 mg kg−1) and xylazine (10 mg kg−1) 
and transcardially perfused with PBS at pH 7.4 followed by 4% 
paraformaldehyde in PBS. Brains were removed and further fixed 
overnight in 4% paraformaldehyde. An HM 450 Sliding Microtome 
(Thermo Scientific) was used to cut coronal sections at 20 µm. Sections 
were blocked with 1% BSA, 2% normal goat serum (NGS), and 0.3% 
TritonX-100 in PBS at room temperature for 1 h and incubated with 
primary antibodies in working buffer (0.1% BSA, 0.2% NGS, and 0.3% 
TritonX-100 in PBS) at 4 °C overnight. The following primary antibodies 
were used: goat anti-IGFBP2 (1:200, Santa Cruz), mouse anti-NeuN 
(1:1000; Millipore), mouse anti-GAD67 (1:500, Millipore), and anti-GFAP 
(1:500, Abcam). Sections were washed four times with working buffer 
for 10 min each, incubated with secondary antibodies conjugated with 
Alexa Fluor 488, 594, or 633-647 (1:500 or 1:1000, Life Technologies) 
in working buffer for 1 h at room temperature, and then washed four 
times with working buffer for 10 min each. Sections were mounted in 
Vectashield mounting medium containing DAPI (1:1000 in PBS, 25 min). 
Images were captured on a Nikon A1R scanning laser microscope or an 
Olympus FV1000/olyVIA microscope using a 60×/100× oil immersion 
objective and processed using MetaMorph software and NIH ImageJ. 
Immunofluorescence images were converted to black-and-white and 
cells were counted with MetaMorph by experimenters blind to the 
test conditions. The total cells and interneurons in the hippocampus 
(SP, SO, SR in CA1, CA3, and the DG) and cortex (L1 and L2/3) 
of igfbp2+/+ and igfbp2−/− mice (p15 and p45) were stained for DAPI 
and GAD67 respectively. Regions of interest (mm2) of CA1, CA3, DG, 
L1, and L2/3) were selected and the number of cells and interneurons 
were counted using MetaMorph image-analysis software. Four sections 
(20 µm, bilateral or left hippocampus and cortex) from each mouse 
(n = 4) were counted and the data are presented as mean ± SEM.
Golgi Staining: Brain tissue was rinsed in impregnation mixing 
Solutions A and B at room temperature for 2 weeks and transferred 
to Solution C for 72 h to 1 week. Sections were cut at 30–40 µm; each 
section was checked under the microscope with Solution C and then 
rinsed in Solutions D and E mixed 10 times (Rapid GolgiStain Kit, PK 
401/401A, FD Neurotechnologies, Inc., Columbia, MD).
Morris Water Maze: Morris water maze tests were performed using 
adult (p45/p60) male control (C57BL/6J) wild-type and igfbp2−/− mice. 
Mice were handled for 5 min each for three consecutive days before 
beginning experiments. The maze consisted of a large circular tank 
(1 m in diameter, 0.5 m high) of water at 25 ± 1 °C made opaque by 
the addition of nontoxic water-based white paint. An escape platform 
(11 cm in diameter) was submerged 0.5–1 cm below the water surface 
in the center of one of the four quadrants and remained in this position 
for each mouse. Several visual cues were placed on the walls of the 
behavioral room as spatial references. An automated tracking system 
(DigBehv-MWM; Jiliang Software Technology Co. Ltd., Shanghai, China) 
monitored performance using the following parameters: escape latency 
(finding the submerged platform), swimming speed, and a visual 
sensitivity test.
Real Time Quantitative RT-PCR: Total RNA was prepared using TRIzol 
reagent (Life Technologies). RNA (2 µL) was reverse-transcribed with the 
TransScript TM RT enzyme mix and then stored at −20 °C. First-strand 
cDNA was subjected to PCR amplification using a Quantitect SYBR 
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Green PCR kit (Qiagen, Valencia, CA). The primer sequences were as 
follows: IGFBP2 (forward: 5′-CTTCCTTCTGGCGTTGGGAG-3′; reverse: 
5′-TTCATGCCTGACTTGAGGGG-3′), IGFR1 (forward: 5′-GACTTCGG 
ACCAGTCTCGC-3′; reverse: 5′-GAGGAGCAAAGCCCAAATCG-3′), CRF 
(forward: 5′-AAAATGTGGATCCAAGGAGGA-3′; reverse:5′-TAGCCA 
CCCCTCAAGAATGAA-3′), CRFR1 (forward:5′-CACTACCATGTTGCA 
GTCATC-3′; reverse: 5′-CGAACATCCAGAAGAAGTTGG-3′), CRFR2 
(forward: 5′-TACCGAATCGCCCTCATTGT-3′; 5′-CCACGCGATGTTT 
CTCAGAAT-3′), SPAR (forward: 5′-GGCAGAGAAGTGAGGACAG-3′; 
reverse: 5′-ATGGCCTTGCTTGTTTGGAG-3′), NR2B (forward: 5′-GGTCTTT 
GCTTCTACGGGCT-3′; reverse: 5′-GTGAGCCAGAGAGCTTCCAG-3′), 
18S RNA (forward: 5′-GTAACCCGTTGAACCCCATT-3′; reverse: 
5′-CCATCCAATCGGTAGTAGCG-3′). Quantitative real-time PCR was 
carried out on a 7500 Real-Time PCR System.
Western Blotting: Hippocampal extracts were obtained by Polytron 
homogenization in cold lysis buffer containing protease and 
phosphatase inhibitors (0.2 m NaCl, 0.1 m HEPES, 10% glycerol, 
2 × 10−3 m NaF, 2 × 10−3 m Na4P2O7, 4 U mL−1 aprotonin, 2 × 10−3 m DTT, 
1 × 10−3 m EGTA, 1 × 10−6 m microcystin, and 1 × 10−3 m benzamidine). 
Protein concentrations were determined using the BioRad protein 
assay (BioRad Laboratories, Hercules, CA). Equal amounts of total 
protein (10–20 µg per lane) were resolved on denaturing SDS-PAGE 
gels and transferred to Hybond-P membranes (Millipore, Billerica, MA) 
by electroblotting. Membranes were dried, reactivated in methanol for 
5 min, and washed with three changes of water. Membranes were then 
blocked in 3% milk/PBS or according to manufacturers’ instructions for 
1 h at room temperature, and incubated with either anti-IGFBP2 (1:200, 
Santa Cruz Biotechnology or Abcam, ab136494), or anti-actin (1:5000, 
Santa Cruz Biotechnology) antisera in PBS overnight at 4 °C. Anti-SPAR 
antibody and Anti-SIPA1 were from Abcam (Ab1925436) and anti-IGFR1 
antibody from Sigma. Colloidal gold total protein stain was from BioRad. 
Membranes were washed, treated with a secondary HRP-labeled donkey 
anti-rabbit antibody (1:4000, GE Healthcare, Waukesha, WI) for 1 h, 
washed again, and incubated with HRP-streptavidin complex and ECL 
detection reagents (GE healthcare, Waukesha, WI).
ELISA: IGFBP2, IGF1, IGF2, and CRF levels in cultured neurons 
and hippocampal tissue supernatants were quantified using ELISA 
as previously described, according to the product protocol (IGFBP2 
ELISA kit: BOSTER, catalog number EK0385; CRF ELISA kit: Peninsula 
Laboratories International, Inc., catalog number S-1181.0001; IGF1 
ELISA kit: Abcam, Ab100695; IGF2 ELISA kit:SEA051Mu, Cloud-clone 
Corp).
Implant Surgery and Stereotactic Microinjection: Hippocampal 
microinjection was performed as previously described. p35 mice were 
implanted with bilateral cannulae aimed at the dorsal hippocampus. 
Animals were anesthetized by sodium pentobarbital (80 µg g−1, i.p.) 
and mounted in a Kopf stereotaxic frame that was used to position the 
24-gauge stainless steel guide cannulae in the dorsal hippocampi (AP 
−1.8 mm, ML ± 1.5 mm, DV −1.3 mm). Coordinates were chosen based 
on a mouse brain atlas. Mice were housed individually and allowed 
at least 7 d of postoperative recovery before being used in behavioral 
experiments. At p42, anti-IGFBP2 antibody (Abcam, ab136494) or 
vehicle (PBS, pH 7.4) was infused into the dorsal hippocampus, then the 
water maze test was performed and hippocampal tissue was removed 
for Western blotting. At p60, peptide fragment IGFBP2[15] (500 × 10−9 m) 
was infused into dorsal hippocampus in WT and KO mice for ELISA and 
Western blotting.
For infusions, the injectors were inserted into the guide cannulae and 
left in place for 1 min followed by a 1 min infusion of antibody (1.5 nmol 
in 0.5 µL per side, dissolved in 500 nL PBS) or vehicle (500 nL of PBS). 
The injectors were left in place for 1 min after the infusion and then 
replaced with obturators. To verify proper placement of the cannulae, 
mice were anesthetized and perfused with 4% paraformaldehyde in PBS 
at the end of the behavioral experiments. Their brains were postfixed 
overnight in the same fixative with 30% sucrose. Coronal sections 
(40 µm) were cut through the hippocampus, stained with cresyl violet, 
and examined under a light microscope. Mice with incorrect cannula 
placements were discarded from the study.
Hypoxia Exposure: After birth, newborn male mice and their 
mothers were immediately exposed to hypoxia simulating an altitude 
of 2000 m (16.0% O2 at sea level) in a well-ventilated hypobaric 
chamber (FLYDWC50-IIC; Avic Guizhou Fenglei Aviation Armament 
Co., Ltd.). Control newborn mice were set at sea level (21.0% O2) in a 
similar chamber. Intermittent hypoxia was applied from 08:00 to 12:00 
daily (4 h per day) as previously described.[37] Mice at p9, p14, p28, 
and p35 were deeply anesthetized with ether and decapitated and the 
hippocampi were removed, immediately frozen in liquid nitrogen, and 
stored at −80 °C.
Drugs and Reagents: All drugs and buffers for intracellular and 
extracellular solutions, as well as ATP, GTP, phosphocreatine, DNQX, 
AP5, and picrotoxin were from Sigma. The synthetic peptide containing 
the heparin-binding domain (amino-acids 196-199) and nine additional 
amino-acids of mouse IGFBP2, 188KHLSLEEPKKLRP200 (referred to 
as HBD peptide),[15] and control peptide for HBD (AALSLEEPAALAP), 
called mutant IGFBP2, were from China Peptide, dissolved in ddH2O 
and stored at −20 °C until use within 6 months of purchase. JB-1 was 
from Bachem. Gabazine, CRF, and TTX were from Tocris Bioscience. 
CP-154,526 was kindly donated[38] by the Pfizer Company (Pfizer Inc., 
Groton, CT, USA).
Statistical Analysis: All data are shown as mean ± SEM. unless 
otherwise noted. P < 0.05 was considered to be statistically significant. 
Data for which a specific P value is not indicated are not significantly 
different (*P < 0.05, **P < 0.01, ***P < 0.001). For electrophysiology 
experiments, significance was determined by the paired two-tailed t-
test for direct comparisons between neurons, the Kolmogorov-Smirnov 
test for frequency and sometimes for amplitude, the two-tailed t-test for 
comparisons between populations, and one-way ANOVA with Bonferroni 
post-hoc for LTP. To assess correlations, the best-fit linear regression 
is shown as indicated in the figure legends. Behavioral assays were 
analyzed by one/two-way ANOVA with the Bonferroni post-hoc test. For 
imaging, qRT-PCR, ELISA, and western blot experiments, significance 
was determined by the two-tailed t-test.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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